Eyüpoğlu, N.D. et al. (2022) “Event-free Survival in Patients with Chronic Myeloid Leukemia Receiving Front-line Imatinib Mesylate”, Acta Medica, 53(3), pp. 277–283. doi:10.32552/2022.ActaMedica.745.